Jeremy Robbins is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
185 Pilgrim Rd
Deaconess 319
Boston, MA 02215
Telephone
617-632-8800Registry record last updated 22 Aug 2018.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Edwards Lifesciences CorporationProgram year202517 payments$17,765openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202511 payments
- Edwards Lifesciences CorporationProgram year202414 payments$20,570openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.1%Beta blocker20.1%Metoprolol Succinate75%Carvedilol25%Part D<11 patientsStatin16.4%Atorvastatin Calcium54%Rosuvastatin Calcium46%Part D≥18 patients+ 9 more classes in this area
Blood & clotting
11%Factor Xa inhibitor11%Eliquis79%Xarelto21%Part D<11 patientsMetabolism & gastrointestinal
8.9%GLP-1 receptor agonist4.8%Ozempic100%Part D<11 patientsSGLT2 inhibitor4.1%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2024 per NIH RePORTER. The latest:
- Integrative analysis of genomics and proteomics to identify candidate molecular transducers of cardiorespiratory fitness
Beth Israel Deaconess Medical Center
FY2024$345,800R03OD038387 - DMGV and the AGXT2 pathway in chronic exercise-induced cardiometabolic adaptations.
Beth Israel Deaconess Medical Center
FY2024$170,424K23HL150327 - DMGV and the AGXT2 pathway in chronic exercise-induced cardiometabolic adaptations.
Beth Israel Deaconess Medical Center
FY2023$170,424K23HL150327
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”